12,372 trials
COVID-19
Primary: Phase 3: Percentage of Participants Who Experience COVID-Related Hospitalization or Death From Any Cause in 2800 mg Bamlanivumab/2800 mg Etesevimab, 700 mg…
Stage II Prostate Adenocarcinoma · Stage III Prostate Adenocarcinoma
Primary: 68Ga-PSMA-11 PET Detection of Prostate Cancer Metastasized to Lymph Nodes — 19 Participants
Chronic Plaque Psoriasis · Moderate to Severe Chronic Plaque Psoriasis · Psoriatic Arthritis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 1.2; 90.8 percentage of participants — p=<0.001
Orthopedic Disorder
Primary: Total Time to Perform the Regional Anesthesia Technique — 3; 6 minutes
Diabetes Mellitus, Type 1
Primary: Change in HbA1c — 0.18; 0.15 percentage of change
Insomnia Disorder
Primary: Total no. of Subjects With at Least One TEAE — 53; 103; 55; 45 Participants
Neutropenia · Breast Cancer
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.31; 0.39 Days — p=< 0.0001
Various Advanced Cancer
Primary: Overall Survival (OS) in Participants With Tumor Cell PD-L1 — 13.70; 15.44; 9.07 Months — p=0.0010
Achondroplasia
Primary: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 — 1.71; 0.13 cm/year — p=< 0.0001
Acute Pain
Primary: Change in Numerical Rating Scale of Pain (NRS) Before Treatment to 60 Minutes After Treatment — 6.2; 5.4 units on a scale — p=0.08
Veno-occlusive Disease
Primary: Veno-occlusive Disease (VOD)-Free Survival by Day +30 Post-Hematopoietic Stem Cell Transplant (HSCT) Per the Independent Endpoint Adjudication Committee (EPAC) — 66.8…
Chronic Plaque Psoriasis · Moderate to Severe Plaque Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 — 86.2; 47.2 percentage of participants — p=<0.001
Muscle Atrophy · ACL Reconstruction · Trauma
Primary: Changes in Lean Mass — 2.8; -0.1; 2.16; 0.01 kg — p=0.35
Neutropenia · Breast Cancer
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.20; 0.35 days — p=<0.0001
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at Week 12 — 13.3; 24.2 percentage of participants — p=0.00006